Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1.       Overview of intrahepatic, perihilar, distal cholangiocarcinoma

2.       Overview of gall bladder adenocarcinoma

3.       Adjuvant chemoradiation and chemotherapy considerations

4.       Per-protocol, intention to treat analysis, historical controls

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022;40(18):2048-2057. doi:10.1200/JCO.21.02568

2.          Primrose JN, Neoptolemos J, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X

3.          Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192-202. doi:10.1002/BJS.10776

4.          Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1). doi:10.1053/J.GASTRO.2012.04.008

5.          Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015-1027. doi:10.1200/JCO.18.02178

6.          Edeline J, Bonnetain F, Phelip JM, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. https://doi.org/101200/JCO2017354_suppl225. 2017;35(4_suppl):225-225. doi:10.1200/JCO.2017.35.4_SUPPL.225

7.          Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-v37. doi:10.1093/ANNONC/MDW324

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       Overview of nomenclature, etiology and presentation

2.       Management of symptoms and prognosis

3.       Systemic therapy in the first line

4.       Second line and biomarker driven management

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Marabelle A et al.. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

2.          Lamarca A et al. The Lancet Oncology. 2021;22(5):690-701. doi:10.1016/S1470-2045

3.          Zia MI, Siu LL, et al. Journal of Clinical Oncology. 2005;23(28):6982-6991. doi:10.1200/JCO.2005.06.679

4.          Phelip JM  et al. J Clin Oncol. 2022;40(3):262-271. doi:10.1200/JCO.21.00679

5.          Valle J et al. NEJM. 2010;362(14):1273-1281. doi:10.1056/NEJMOA0908721

6.          Oh DY et al. NEJM Evidence.  Published online June 1, 2022.  doi:https://doi.org/10.1056/EVIDoa2200015

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1.       Differential for pancreatic lesion, staging of adenocarcinoma

2.       Surgical considerations, post-surgical complications

3.       Historical adjuvant evidence

4.       An argument for neoadjuvant systemic therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Fietkau  et al. Rl. J Clin Oncol 2022;40(16_suppl) doi:10.1200/JCO.2022.40.16_SUPPL.4008

2.          Conroy T et al. F NE JMe. 2018;379(25):2395-2406. doi:10.1056/NEJMOA1809775/

3.          Tempero MA et al. J Clin Oncol. 2019;37(15_suppl) doi:10.1200/JCO.2019.37.15_SUPPL.4000

4.          Neoptolemos JP et al. The Lancet. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6/ATTACHMENT/46BFFE67-D3AE-4DEA-822B-4A2CE28139FD/MMC1.PDF

5.          Liao WC et al.  Lancet Oncol. 2013;14(11):1095-1103. doi:10.1016/S1470-2045(13)70388-7

6.          van Laethem JL et al.  J Clin Oncol. 2010;28(29):4450-4456. doi:10.1200/JCO.2010.30.3446

7.          Evans DB et al. Annals of Surgery. 2000;232(5):727. doi:10.1097/00000658-199912000-00006

8.          Kaiser M,  Ellenberg S. Arch Surg. 1985;120(8):899-903. doi:10.1001/ARCHSURG.1985.01390320023003

9.          van Dam JL  et al. Eur J Cancer. 2022;160:140-149. doi:10.1016/J.EJCA.2021.10.023

10.        Versteijne E et al.  J Clin Oncol. 2022;40(11):1220-1230. doi:10.1200/JCO.21.02233

11.        Neoptolemos  et al.  NEJM. 2004;350(12):1200-1210. doi:10.1056/NEJMOA032295

12.        Neoptolemos JP et al. Lancet. 2001;358(9293):1576-1585. doi:10.1016/S0140-6736(01)06651-X

 Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1.      Natural history of disease, presentation, and diagnosis

2.      Principles of management

3.      Landmark clinical trials

4.      Targeted therapy options as of 2022

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Golan T et al.  N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMOA1903387/

2.          Von Hoff DD et al. N Engl J Med. 2013;369(18):1691-1703. doi:10.1056/NEJMOA1304369/

3.          Conroy T et al. N Engl J Med. 2011;364(19):1817-1825. doi:10.1056/NEJMOA1011923/

4.          Carmichael J et al. Br J Cancer. 1996;73(1):101. doi:10.1038/BJC.1996.18

5.          Casper ES et al. Investig New Drugs 1994 121. 1994;12(1):29-34. doi:10.1007/BF00873232

6.          Rothenberg ML et al. Ann Oncol. 1996;7(4):347-353. doi:10.1093/OXFORDJOURNALS.ANNONC.A010600

7.          New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development | Division of Cancer Prevention. https://prevention.cancer.gov/news-and-events/blog/new-onset-diabetes-cohort. Accessed June 13, 2022.

8.          McGuigan A et al. W J Gastroenterology. 2018;24(43):4846-4861. doi:10.3748/WJG.V24.I43.4846

9.          Kamisawa T et al. Pancreatic cancer. Lancet. 2016;388(10039):73-85. doi:10.1016/S0140-6736(16)00141-0

10.       Siegel RL et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/CAAC.21708

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.      Principles of management

2.      Key chemotherapy tegimens

3.      Immunotherapy/HER-2 Directed Approach

4.      Alpha spending, hierarchical statistical design

5.      Later line approach and bottom lines to approach

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Veer E ter et al. J Natl Cancer Inst. 2016;108(10). doi:10.1093/JNCI/DJW166

2.          Guimbaud R et al. J Clin Oncol. 2014;32(31):3520-3526. doi:10.1200/JCO.2013.54.1011

3.          Cunningham D et al. NEJM. 2008;358(1):36-46. DOI: 10.1056/NEJMoa073149

4.          Wagner AD et al. J Clin Oncol. 2006;24(18):2903-2909. doi:10.1200/JCO.2005.05.0245

5.          Janjigian YY et al. Lancet Oncol. 2020;21(6):821-831. doi:10.1016/S1470-2045(20)30169-8

6.          ter Veer et al. Int J Cancer. 2018;143(2):438-448. doi:10.1002/IJC.31325

7.          Doki Y et al. NEJM. 2022;386(5):449-462. doi: 10.1056/NEJMoa2111380. 

8.          Shitara K et al. NEJM. 2020;382(25):2419-2430. DOI: 10.1056/NEJMoa2004413 

9.          Wilke H et al. The Lancet Oncology. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6

10.       Chao J et al. JAMA Oncol. 2021;7(6):895-902. doi:10.1001/JAMAONCOL.2021.0275

11.       Janjigian YY et al. Lancet. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2

12.       Shitara K  et al. Nature. 2022;603:7903. doi:10.1038/s41586-022-04508-4

13.       Sun JM  et al. The Lancet. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4

14.       Shitara K,  et al. JAMA Oncology. 2020;6(10):1571-1580. doi:10.1001/JAMAONCOL.2020.3370

15.       Bang YJ et al.   Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X

 Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1.       Anatomy of the Upper GI Tract

2.       Diagnosis, Staging Work-up

3.       Neoadjuvant Chemoradiation for Esophageal/EGJ

4.       Perioperative and Adjuvant Gastric/EGJ

5.       Checkmate 577 discussion

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Ronellenfitsch U et al. Eur J Cancer. 2019;123:101-111. doi:10.1016/J.EJCA.2019.10.001

2.          Ohn J et al. NEJM 2009;345(10):725-730. doi:10.1056/NEJMOA010187

3.          Ell C et al. Gastroenterology. 2000;118(4):670-677. doi:10.1016/S0016-5085(00)70136-3

4.          al-Sarraf M et al. J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277

5.          Oba K et al. J Natl Cancer Inst. 2013;105(21):1600-1607. doi:10.1093/JNCI/DJT270

6.          Bang YJ et al. Lancet. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4

7.          Smalley SR et al.  Journal of Clinical Oncology. 2012;30(19):2327. doi:10.1200/JCO.2011.36.7136

8.          Petrelli F et al. Eur J Cancer. 2017;76:8-16. doi:10.1016/J.EJCA.2017.01.032

9.          Kelly RJ et al. NEJM 2021;384(13):1191-1203. doi:10.1056/NEJMOA2032125/

10.        Al-Batran SE et al. The Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1

11.        al-Sarraf M et al.J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277

12.        Cunningham D et al. NEJM.  2009;355(1):11-20. doi:10.1056/NEJMOA055531

13.        JS C, et al.  JAMA. 1999;281(17):535-547. doi:10.1001/JAMA.281.17.1623

14.        Park SH et al. J Clin Oncol. 2021;32(3):368-374. doi: 10.1016/j.annonc.2020.11.017

15.        Lee J et al. Journal of Clinical Oncology. 2012;30(3):268-273. doi:10.1200/JCO.2011.39.1953

16.        Cats A et al. The Lancet Oncology. 2018;19(5):616-628. doi:10.1016/S1470-2045(18)30132-3

20.          van Hagen P et al. NEJM. 2012;366(22):2074-2084. doi: 10.1056/NEJMoa1112088

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

IDEA Trial Discussion

1.      Background/Methods

2.      Non-inferiority Trial Design

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Grothey A et al.  NEJM.  2018;378:1177-1188. doi:10.1056/NEJMoa1713709

2.          Andre PT et al.  Lancet Oncol. 2020;21(12):1620-1629. doi:https://doi.org/10.1016/S1470-2045(20)30527-1

3.          Mauri LM and D’Agostino RB.  NEJM.  2017;377:1357-1367. doi: 10.1056/NEJMra1510063

4.            Hahn S.  Korean J Pediatr.  2012;55(11):403-407. doi: 10.3345/kjp.2012.55.11.403

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1.      Clinical Presentation, Pathology Evaluation

2.      Chemotherapy Regimens in Adjuvant Setting

3.      Approach to Stage 3

4.      Approach to Stage 2

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Practice Tools for the prognostic of Colorectal Cancer. Accessed April 2, 2022. https://oncologypro.esmo.org/oncology-in-practice/practice-tools/colorectal-cancer-prognosis

2.          Haller DG et al. Ann Oncol. 2015;26(4):715-724. doi:10.1093/ANNONC/MDV003

3.          Babcock BD et al. Ann Surg Oncol. 2018;25(7):1980-1985. doi:10.1245/S10434-018-6484-8

4.          Moertel CG et al. NEJM. 2010;322(6):352-358. doi:10.1056/NEJM199002083220602

5.          Ribic CM et al. NEJM. 2003;349(3):247-257. doi:10.1056/NEJMOA022289

6.          Haller DG et al. J Clin Oncol. 2005;23(34):8671-8678. doi:10.1200/JCO.2004.00.5686

7.          Kuebler JP et al. J Clin Oncol. 2007;25(16):2198-2204. doi:10.1200/JCO.2006.08.2974

8.          André T et al. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771

9.          Sargent DJ et al. J Clin Oncol. 2005;23(34):8664-8670. doi:10.1200/JCO.2005.01.6071

10.       Kannarkatt J et al. J Oncol Pract. 2017;13(4):233-241. doi:10.1200/JOP.2016.017210

11.       Grothey A et al. NEJM. 2018;378(13):1177-1188. 

12.       André T et al. Lancet Oncol. 2020;21(12):1620-1629. doi:10.1016/S1470-2045(20)30527-1

13.       André T et al. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771

14.       André T et al. Oxaliplatin, NEJM 2009;350(23):2343-2351. doi:10.1056/NEJMOA032709

15.       Buyse M et al. Stat Methods Med Res. 2008;17(5):467-475. doi:10.1177/0962280207081864

16.       Sargent D et al. Eur J Cancer. 2011;47(7):990. doi:10.1016/J.EJCA.2010.12.015

17.       Gray R et al. Lancet. 2007;370(9604):2020-2029. doi:10.1016/S0140-6736(07)61866-2

 Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1.      Background on molecular targeted agents

2.      VEGF-inhibitors

3.      EGFR inhibition

4.      Left vs Right sided colon cancer

5.      MSI-H/dMMR status

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

 1.          Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5

2.          Deng  T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z

3.          Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691

4.          Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9

5.          Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060

6.          Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930

7.          Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520

8.          Tang W et al.  J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174

9.          Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305

10.       van Cutsem E et al. NEJM. 2009;360(14):1408-1417. 

11.       Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570

12.       Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057

13.       Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797

14.       Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105

15.       Maughan TS et al.   The Lancet. 2011;377(9783):2103-2114

16.       Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258

17.       Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19

18.       Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6

19.       André T et al. NEJM  2020;383(23):2207-2218. 

20.       Jonker DJ  al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834

21.       Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015

22.       Tol J et al. NEJM. 2009;360(6):563-572. 

 Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

1.      Clinical presentations of metastatic colon cancer

2.      ECOG performance status

3.      5-fluorouracil and capecitabine

4.      Doublet Regimens (FOLFOX/FOLFIRI and derivatives)

5.      FOLFOXIRI

6.      Considerations for elderly/frail patients

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode

1.          Cremolini C,  et al. Lancet Oncol. 2020;21(4):497-507. doi:10.1016/S1470-2045(19)30862-9

2.          Cremolini C et al. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9

3.          Sobrero AF et al. J Clin Oncol. 2016;15(1):368-381. doi:10.1200/JCO.1997.15.1.368

4.          Pinedo HM, Peters GFJ. J Clin Oncol. 1988;6(10):1653-1664. doi:10.1200/JCO.1988.6.10.1653

5.          Loriot MA,  et al. Bulletin du Cancer. 2018;105(4):397-407. doi:10.1016/J.BULCAN.2018.02.001

6.          Pachman DR et al. J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533

7.          Eonard L et al. NEJM. 2009;343(13):905-914. doi:10.1056/NEJM200009283431302

8.          Falcone A et al. J Clin Oncol. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928

9.          Tournigand C et al. J Clin Oncol. 2004;22(2):229-237. doi:10.1200/JCO.2004.05.113

10.       Group NGTAT. J Clin Oncol. 2016;10(6):904-911. doi:10.1200/JCO.1992.10.6.904

11.       Jang RW et al. J Oncol Practice. 2014;10(5):e335-e341. doi:10.1200/JOP.2014.001457

12.       Simmonds PC, et al. B J Cancer 2006 94:7. 2006;94(7):982-999. doi:10.1038/sj.bjc.6603033

13.       Douillard JY et al. Lancet. 2000;355(9209):1041-1047. doi:10.1016/S0140-6736(00)02034-1

14.       de Gramont A et al. J Clin Oncol. 2016;15(2):808-815. doi:10.1200/JCO.1997.15.2.808

15.       O’connell MJ. Cancer. 1989;63:1026-1030. doi:10.1002/1097-0142

16.       Poon MA et al. J Clin Oncol. 2016;7(10):1407-1418. doi:10.1200/JCO.1989.7.10.1407

 Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.